3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase NA
3
Phase 1/2
3
Phase 4
2
Phase 1
2
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
83
Lymphoid
80
Breast
28
Myeloid
16
Sarcoma
8
Head & Neck
8
Genitourinary
5
Classical hematology
5
CNS
5
Gynecologic
3
Plasma cell
1
Dermatologic
1
Conditions
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Interventions
Dacarbazine
27
Nivolumab
26
pembrolizumab
22
Ipilimumab
20
3-ingenyl angelate
11
Interferon-alpha
10
Imiquimod
10
Temozolomide
9
trametinib
8
Vemurafenib
8
Photochemotherapy
8
Aminolevulinic Acid
8
methyl 5-aminolevulinate
7
dabrafenib
7
cemiplimab
7
aldesleukin
7
Introns
7
Surgical Procedures, Operative
6
Radiotherapy
6
Interferon alpha-2
6
Fluorouracil
6
Paclitaxel
5
Melphalan
5
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
binimetinib
4
Specimen Handling
4
Opdualag
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Methotrexate
×
Dermatologic
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts